Name: ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock
Brand: ADAPTIVE BIOTECHNOLOGIES
Rating: 6.5 (3 reviews)

ADPT Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

2 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

14 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

14 days ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

a month ago - By: Benzinga - Mentions: TECH INSE GEF SKYT ...

Earnings Scheduled For November 5, 2025

a month ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

a month ago - By: Zacks Investment Research

Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say

a month ago - By: Zacks Investment Research - Mentions: CUE

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

a month ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

2 months ago - By: Benzinga

A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts

4 months ago - By: The Motley Fool

Adaptive (ADPT) Q2 Revenue Surges 36%

a month ago - By: Zacks Investment Research - Mentions: ZYME

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

a month ago - By: Zacks Investment Research - Mentions: EXEL

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

2 months ago - By: Zacks Investment Research - Mentions: ALNY IQV

IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?

2 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

2 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

3 months ago - By: Zacks Investment Research - Mentions: RARE IONS AKRO

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

3 months ago - By: Zacks Investment Research - Mentions: CAH

Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

3 months ago - By: Zacks Investment Research - Mentions: AQST ALLO AKRO

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

3 months ago - By: Zacks Investment Research - Mentions: AGIO ALLO AKRO

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

3 months ago - By: Zacks Investment Research - Mentions: REGN SNY AKRO

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

3 months ago - By: Zacks Investment Research - Mentions: SNY AKRO ALGS

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

3 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice

3 months ago - By: Zacks Investment Research - Mentions: ANIP

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

3 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

3 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

4 months ago - By: Zacks Investment Research - Mentions: PBYI

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

4 months ago - By: Zacks Investment Research - Mentions: CAH

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?

4 months ago - By: Yahoo Finance

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

4 months ago - By: The Motley Fool

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

4 months ago - By: Zacks Investment Research

Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings

4 months ago - By: Zacks Investment Research - Mentions: ACAD

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Adaptive Biotechnologies

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

4 months ago - By: Zacks Investment Research - Mentions: MRNA

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock News

ADPT Latest News, Press Relases and Analysis

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Earnings Scheduled For November 5, 2025

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies (ADPT) Reports Q3 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

A Glimpse Into The Expert Outlook On Adaptive Biotechnologies Through 4 Analysts

Adaptive (ADPT) Q2 Revenue Surges 36%

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

Are You Looking for a Top Momentum Pick? Why Adaptive Biotechnologies (ADPT) is a Great Choice

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

Why Adaptive Biotechnologies Stock Popped by Almost 6% on Wednesday

Here's What Key Metrics Tell Us About Adaptive Biotechnologies (ADPT) Q2 Earnings

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates